AURE (AURE) Stock Price & Analysis
AURE (AURE) fell 3.95% to USD 1.7 as of July 25, 2026 at 16:30 UTC, according to Nexqual real-time market data.
AURE last closed at USD 1.77; the session ranged USD 1.7–1.73 on volume of 3,149 shares. Market capitalization is $62.56M, with a 52-week range of USD 1.25–14.6 (NCM). Source: Nexqual, July 25, 2026 at 16:30 UTC.
Key Statistics (as of July 25, 2026 at 16:30 UTC)
| Price | USD 1.7 |
|---|---|
| Change | ▼ 3.95% (down) |
| Previous Close | USD 1.77 |
| Open | USD 1.72 |
| Day Range | USD 1.7 – 1.73 |
| 52-Week Range | USD 1.25 – 14.6 |
| Volume | 3,149 shares |
| Market Cap | $62.56M |
| Exchange | NCM |
Technical Analysis (AURE)
Nexqual's technical model rates AURE "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 16:30 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.95 (neutral) |
| vs SMA50 | Below (USD 2.19) |
| MACD | -0.14 (negative) |
Analyst Ratings (AURE)
Wall Street analysts rate AURE "None", per Nexqual as of July 25, 2026 at 16:30 UTC.
| Consensus Rating | None |
|---|
Earnings (AURE)
Source: Nexqual, July 25, 2026 at 16:30 UTC.
Financials & Fundamentals (AURE)
| Total Revenue | $1.79M |
|---|---|
| Gross Margin | -130.14% |
| Operating Margin | +505.91% |
| Profit Margin | -136.76% |
| ROE | -3.60% |
| Debt / Equity | 35.66 |
| Current Ratio | 59.94 |
| Total Cash | $2.07M |
| Total Debt | $41.20M |
| Free Cash Flow | $-67.92M |
Source: Nexqual, July 25, 2026 at 16:30 UTC.
Financial Health Score (AURE)
Nexqual rates AURE's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 16:30 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $2M cash vs $41M debt |
| Cash Flow | Weak — FCF negative: -$68M, burning cash |
| Efficiency | Critical — ROE -4%, ROA 6.4% |
Ownership (AURE)
| Insider Ownership | +22.04% |
|---|---|
| Institutional Ownership | +12.91% |
| Shares Outstanding | 21.55M |
| Float | 7.97M |
| Short % of Float | +0.24% |
Source: Nexqual, July 25, 2026 at 16:30 UTC.
Leadership (AURE)
AURE is led by Xiang Zheng, Chief Executive Officer, per Nexqual as of July 25, 2026 at 16:30 UTC.
| Chief Executive Officer | Xiang Zheng |
|---|
Major Backers & Investors (AURE)
Notable institutional backers of AURE include Yorkville Advisors Global, LP, according to Nexqual as of July 25, 2026 at 16:30 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Yorkville Advisors Global, LP | 12.88% |
Source: Nexqual, July 25, 2026 at 16:30 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BGLC | BioNexus Gene Lab Corp | USD 1.51 | ▼ 1.95% |
| MGIH | Millennium Group International | USD 1.62 | ▼ 2.41% |
| VCIG | VCI Global Limited | USD 0.51 | ▼ 24.83% |
| SXTP | 60 Degrees Pharmaceuticals, Inc | USD 1.48 | ▼ 4.52% |
| GDC | GD Culture Group Limited | USD 1.7 | ▼ 12.37% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 16:30 UTC. This page is informational and not investment advice.